MENOGARIL IN THE TREATMENT OF RELAPSED MULTIPLE-MYELOMA - A PHASE-II TRIAL OF THE CANCER CENTER OF WAKE-FOREST-UNIVERSITY

被引：1

作者：

CRUZ, JM ^{[1
]}

CASE, LD ^{[1
]}

DALTON, HB ^{[1
]}

RAMSEUR, WL ^{[1
]}

RICHARDS, F ^{[1
]}

JACKSON, DV ^{[1
]}

MUSS, HB ^{[1
]}

ZEKAN, PJ ^{[1
]}

BRODKIN, RA ^{[1
]}

BROWN, RC ^{[1
]}

HERRING, WB ^{[1
]}

LUSK, JA ^{[1
]}

OROURKE, MA ^{[1
]}

REDDY, SM ^{[1
]}

CAPIZZI, RL ^{[1
]}

机构：

[1] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103

来源：

INVESTIGATIONAL NEW DRUGS | 1992年 / 10卷 / 01期

关键词：

MENOGARIL; MULTIPLE MYELOMA;

D O I：

10.1007/BF01275478

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39 + months. Menogaril displays little activity in patients with previously treated MM.

引用

页码：35 / 37

页数：3

共 50 条

[1] PHASE-II TRIAL OF AMSACRINE IN PATIENTS WITH MULTIPLE-MYELOMA
GREIPP, PR
COLEMAN, M
ANDERSON, K
MCINTYRE, OR
MEDICAL AND PEDIATRIC ONCOLOGY, 1989, 17 (01): : 76 - 78
[2] ETOPOSIDE PLUS IDARUBICIN AND PREDNISONE IN REFRACTORY OR RELAPSED MULTIPLE-MYELOMA - A PHASE-II STUDY
CAPNIST, G
CHISESI, T
HAEMATOLOGICA, 1988, 73 (05) : 431 - 432
[3] PHASE-II TRIAL OF MENOGARIL IN ADVANCED COLORECTAL-CANCER
HOLDENER, EE
HUININK, WWT
DECOSTER, G
LUDWIG, C
RENARD, G
PINEDO, HM
INVESTIGATIONAL NEW DRUGS, 1988, 6 (03) : 227 - 230
[4] PHASE-II EVALUATION OF CHLOROZOTOCIN IN REFRACTORY MULTIPLE-MYELOMA
FORMAN, WB
COHEN, HJ
BARTOLUCCI, AA
MANNING, G
CANCER TREATMENT REPORTS, 1984, 68 (11): : 1409 - 1410
[5] A PHASE-II STUDY OF IDARUBICIN AND PREDNISONE IN MULTIPLE-MYELOMA
ALBERTS, AS
FALKSON, G
RAPOPORT, BL
UYS, A
TUMORI, 1990, 76 (05) : 465 - 466
[6] PHASE-II EVALUATION OF ACLARUBICIN IN REFRACTORY MULTIPLE-MYELOMA - A SOUTHEASTERN-CANCER-STUDY-GROUP TRIAL
GOCKERMAN, JP
SILBERMAN, H
BARTOLUCCI, AA
CANCER TREATMENT REPORTS, 1987, 71 (7-8): : 773 - 774
[7] PHASE-II EVALUATION OF ETOPOSIDE IN REFRACTORY MULTIPLE-MYELOMA - A SOUTHEASTERN CANCER STUDY-GROUP TRIAL
GOCKERMAN, JP
BARTOLUCCI, AA
NELSON, MO
SILBERMAN, H
VELEZGARCIA, E
STEIN, R
CANCER TREATMENT REPORTS, 1986, 70 (06): : 801 - 802
[8] CARBOPLATIN IN PREVIOUSLY TREATED MULTIPLE-MYELOMA - A CANCER AND LEUKEMIA GROUP-B PHASE-II TRIAL
OMURA, GA
PERRI, RT
PETERSON, B
SCHIFFER, CA
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (03): : 196 - 198
[9] PHASE-II TRIAL OF PYRAZOFURIN IN PATIENTS WITH MULTIPLE-MYELOMA REFRACTORY TO STANDARD CYTOTOXIC THERAPY
LAKELEWIN, D
MYERS, J
LEE, BJ
YOUNG, CW
CANCER TREATMENT REPORTS, 1979, 63 (08): : 1403 - 1404
[10] PHASE-II TRIAL OF MITOXANTRONE IN MULTIPLE-MYELOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
ALBERTS, DS
BALCERZAK, SP
BONNET, JD
STEPHENS, RL
CANCER TREATMENT REPORTS, 1985, 69 (11): : 1321 - 1323

← 1 2 3 4 5 →